Diane L. Costanzo-Garvey

This study uses an immunocompetent mouse model to show that Degarelix-induced chemical castration suppresses prostate cancer tumor growth initially but leads to acquired resistance over time.

This paper establishes patient-derived models of neuroendocrine prostate cancer (NEPC) from metastases, showing they retain tumor heterogeneity and can model metastatic progression.